Colonization by Pneumocystis Jirovecii and Its Role in Disease

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2012 Apr 12

PMID 22491773

Citations 175

Authors

Alison Morris

Karen A Norris

Affiliations

Soon will be listed here.

Abstract

Although the incidence of Pneumocystis pneumonia (PCP) has decreased since the introduction of combination antiretroviral therapy, it remains an important cause of disease in both HIV-infected and non-HIV-infected immunosuppressed populations. The epidemiology of PCP has shifted over the course of the HIV epidemic both from changes in HIV and PCP treatment and prevention and from changes in critical care medicine. Although less common in non-HIV-infected immunosuppressed patients, PCP is now more frequently seen due to the increasing numbers of organ transplants and development of novel immunotherapies. New diagnostic and treatment modalities are under investigation. The immune response is critical in preventing this disease but also results in lung damage, and future work may offer potential areas for vaccine development or immunomodulatory therapy. Colonization with Pneumocystis is an area of increasing clinical and research interest and may be important in development of lung diseases such as chronic obstructive pulmonary disease. In this review, we discuss current clinical and research topics in the study of Pneumocystis and highlight areas for future research.

Citing Articles

An overview of the laboratory diagnosis of pneumonia.

Jaramillo Cartagena A, Asowata O, Ng D, Babady N J Clin Microbiol. 2025; 63(3):e0036124.

PMID: 39898657 PMC: 11898755. DOI: 10.1128/jcm.00361-24.

Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology.

de Hoog S, Walsh T, Ahmed S, Alastruey-Izquierdo A, Arendrup M, Borman A J Clin Microbiol. 2024; 62(12):e0093724.

PMID: 39526838 PMC: 11633119. DOI: 10.1128/jcm.00937-24.

Outcome of Pneumocystis Jirovecii pneumonia (PcP) in post-CAR-T patients with hematological malignancies.

Zu C, Li W, Zhang M, Dong Y, Fu S, Feng J BMC Infect Dis. 2024; 24(1):1147.

PMID: 39396970 PMC: 11472446. DOI: 10.1186/s12879-024-09893-x.

Quantitative real time PCR for distinction between infection/colonization in hospitalized patients.

Rouhi F, Erami M, Rastgufar S, Jahani M, Aboutalebian S, Soltani S Front Cell Infect Microbiol. 2024; 14:1426200.

PMID: 39380728 PMC: 11458531. DOI: 10.3389/fcimb.2024.1426200.

Comparison of High-Dose versus Low-Dose Trimethoprim-Sulfamethoxazole for Treating Pneumonia among Hemodialysis Patients: A Nationwide Database Study in Japan.

Shuto H, Omori S, Hiramatsu K, Kadota J, Fushimi K, Komiya K J Clin Med. 2024; 13(18).

PMID: 39336952 PMC: 11432082. DOI: 10.3390/jcm13185463.

References

Rodriguez M, Fishman J . Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004; 17(4):770-82, table of contents. PMC: 523555. DOI: 10.1128/CMR.17.4.770-782.2004. View

Gigliotti F . Host species-specific antigenic variation of a mannosylated surface glycoprotein of Pneumocystis carinii. J Infect Dis. 1992; 165(2):329-36. DOI: 10.1093/infdis/165.2.329. View

Simonds R, Oxtoby M, Caldwell M, Gwinn M, Rogers M . Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA. 1993; 270(4):470-3. View

Benfield T, Atzori C, Miller R, Helweg-Larsen J . Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008; 48(1):63-7. DOI: 10.1097/QAI.0b013e31816de84d. View

Garvy B, Wiley J, Gigliotti F, Harmsen A . Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun. 1997; 65(12):5052-6. PMC: 175728. DOI: 10.1128/iai.65.12.5052-5056.1997. View

Totet A, Meliani L, Lacube P, Pautard J, Raccurt C, Roux P . Immunocompetent infants as a human reservoir for Pneumocystis jirovecii: rapid screening by non-invasive sampling and real-time PCR at the mitochondrial large subunit rRNA gene. J Eukaryot Microbiol. 2004; 50 Suppl:668-9. DOI: 10.1111/j.1550-7408.2003.tb00678.x. View

Kagi M, Fierz W, Grob P, Russi E . High proportion of gamma-delta T cell receptor positive T cells in bronchoalveolar lavage and peripheral blood of HIV-infected patients with Pneumocystis carinii pneumonias. Respiration. 1993; 60(3):170-7. DOI: 10.1159/000196194. View

Benfield T, Lundgren B, Levine S, Kronborg G, Shelhamer J, Lundgren J . The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect Immun. 1997; 65(11):4790-4. PMC: 175687. DOI: 10.1128/iai.65.11.4790-4794.1997. View

Bartlett M, Angus W, SHAW M, Durant P, Lee C, Pascale J . Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. Clin Diagn Lab Immunol. 1998; 5(1):74-7. PMC: 121395. DOI: 10.1128/CDLI.5.1.74-77.1998. View

10.

Leigh T, Kangro H, Gazzard B, Jeffries D, Collins J . DNA amplification by the polymerase chain reaction to detect sub-clinical Pneumocystis carinii colonization in HIV-positive and HIV-negative male homosexuals with and without respiratory symptoms. Respir Med. 1993; 87(7):525-9. DOI: 10.1016/0954-6111(93)90008-n. View

11.

Desmet S, Van Wijngaerden E, Maertens J, Verhaegen J, Verbeken E, De Munter P . Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. 2009; 47(12):3871-4. PMC: 2786638. DOI: 10.1128/JCM.01756-09. View

12.

Powles M, Liberator P, Anderson J, KARKHANIS Y, Dropinski J, Bouffard F . Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother. 1998; 42(8):1985-9. PMC: 105720. DOI: 10.1128/AAC.42.8.1985. View

13.

Vidal S, de la Horra C, Martin J, Montes-Cano M, Rodriguez E, Respaldiza N . Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect. 2006; 12(3):231-5. DOI: 10.1111/j.1469-0691.2005.01337.x. View

14.

Calderon E . Pneumocystis infection: seeing beyond the tip of the iceberg. Clin Infect Dis. 2010; 50(3):354-6. DOI: 10.1086/649870. View

15.

Mori H, Ohno Y, Ito F, Endo J, Yanase K, Funaguchi N . Polymerase chain reaction positivity of Pneumocystis jirovecii during primary lung cancer treatment. Jpn J Clin Oncol. 2010; 40(7):658-62. DOI: 10.1093/jjco/hyq040. View

16.

Jones T . The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med Oncol. 1996; 13(3):141-7. PMC: 7102098. DOI: 10.1007/BF02990842. View

17.

Hugle B, Solomon M, Harvey E, James A, Wadhwa A, Amin R . Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken). 2010; 62(11):1661-4. DOI: 10.1002/acr.20279. View

18.

Olsson M, Lidman C, Latouche S, Bjorkman A, Roux P, Linder E . Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol. 1998; 36(6):1737-40. PMC: 104910. DOI: 10.1128/JCM.36.6.1737-1740.1998. View

19.

Afessa B, Green B . Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest. 2000; 118(1):138-45. DOI: 10.1378/chest.118.1.138. View

20.

Gingo M, Lucht L, Daly K, Djawe K, Palella F, Abraham A . Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia. J Acquir Immune Defic Syndr. 2011; 57(3):190-6. PMC: 3150634. DOI: 10.1097/QAI.0b013e3182167516. View